Erythropoietin (EPO) is an essential growth factor that regulates erythrocyte production in mammals. In this study, we demonstrate a novel role of EPO in regulating angiogenesis in vivo. Epo and Epo receptor (EpoR) are expressed in the vasculature during embryogenesis. Deletion of Epo or EpoR leads to angiogenic defects starting at E10.5, 2 days before ventricular hypoplasia and 3 days before the onset of the embryonic lethal phenotype. Overall, angiogenesis was severely affected in the mutant embryos: vascular anomalies included decreased complexity of the vessel networks. However, de novo vasculogenesis remained intact, consistent with the differential expression of Epo and EpoR during the early stages of embryonic development. The aforementioned angiogenesis defect can be partially rescued by expressing human EPO during embryogenesis. Moreover, Ang-1 expression is regulated by EPO/EPOR under normoxic conditions. Taken together, our results suggest important roles of EPO and EPOR in angiogenesis. D
Introduction
Erythropoietin is a principal hematopoietic growth factor responsible for the proliferation, survival, and differentiation of erythroid progenitor cells. Through specific binding to its cognate receptor, EPOR (D'Andrea et al., 1989a,b) , EPO triggers a chain of intracellular signaling events, including activation of the receptor-associated tyrosine kinase JAK2 and phosphorylation and nuclear translocation of STAT5, leading to progenitor cell proliferation and differentiation (Watowich et al., 1996) . In addition to erythropoiesis, EPO has been found to be important for megakaryocyte proliferation and differentiation.
Recent studies suggest that the functions of EPO and EPOR are not strictly limited to erythroid or hematopoietic lineages. For instance, EpoR expression has been detected in umbilical cord and placental endothelial cell lines, and EPO was capable of stimulating endothelial cell prolifer-ation in vitro (Anagnostou et al., 1990 (Anagnostou et al., , 1994 . In addition, EPO was known to induce a pro-angiogenic phenotype in cultured endothelial cells and stimulated neo-vascularization in the chick chorioallantoic membrane (Ribatti et al., 1999) . EPO plays an important role in cardiac morphogenesis (Wu et al., 1999) , in myoblast proliferation (Ogilvie et al., 2000) , and possibly in neurogenesis (Yu et al., 2002) . Despite these advances, a detailed analysis of Epo and EpoR expression patterns and their in vivo functions in these non-erythroid lineages are currently lacking.
To understand the possible roles of EPO in these nonhematopoietic lineages and during embryogenesis, we have performed a detailed in situ hybridization analysis comparing the expression profiles of Epo and EpoR from 6.5 to 11.5 dpc. High levels of Epo and EpoR expression can be detected in the vasculature and the heart. Consistent with their expression patterns, we found that Epo and EpoR null embryos are defective in angiogenesis while relatively normal in vasculogenesis. Thus, our results provide the first in vivo evidence for the functions of EPO and EPOR in vivo in angiogenesis.
Materials and methods

Animal breeding and embryo harvesting
Mice with deletions in the Epo or EpoR genes have been described (Wu et al., 1995 (Wu et al., , 1999 . The morning when the vaginal plug could be detected was defined as embryonic day 0.5 (E0.5). Somite and presomite embryos were staged according to criteria previously described (Downs and Davies, 1993) .
In situ hybridization
Embryos were fixed overnight in 4% paraformaldehyde (in PBS) at 48C. Nonradioactive whole-mount mRNA in situ hybridization technique was performed as previously described (Belo et al., 1997) . Digoxigenin-labeled riboprobes were synthesized from a BamH1/EcoR1 500-bp fragment of murine Epo cDNA corresponding to exons 4 and 5, and a XhoI/HindIII 949-bp fragment corresponding to 270-1219 of the EpoR cDNA (Lee et al., 2001) . Embryos, post in situ hybridization, were embedded in liquid paraplast and sectioned at 7 Am. The sections were photographed.
Histology and immunohistochemistry
Whole-mount immunohistochemistry for visualization of vasculature was performed according to protocol described by Koblizek et al. (1998) using an antibody specific to mouse PECAM (anti-CD31, Pharmingen). HRP-conjugated secondary Antibody (Roche) was used followed by DAB staining.
Northern blot analysis
RNA was isolated with Qiagen RNA miniprep kit according to the manufacturer's protocol. Total RNA were separated by a 1% agarose gel and transferred onto a nylon membrane. The RNA was immobilized on the membrane by UV cross-linking and dried at 808C for 2 h. The blot was prehybridized at 658C in QuickHyb hybridization solution (Stratagene) for 30 min and then hybridized for 1 h with VEGF and Ang-1 cDNA probes labeled with [a-32 P] dCTP by using a random primer labeling kit (Stratagene). The blot was washed as recommended by Stratagene. Hybridization signals were visualized by radiography and quantified using Scion Image software (NIH, Bethesda, MD), using a Kodak gray color scale as a standard. Each membrane was stripped and reprobed with labeled actin probe for loading control.
HUVEC cell culture
Normal HUVEC were obtained from Cambrex (Bio-Whittaker) and maintained in EBM2 medium supplemented with 0.1 mg/ml endothelial cell growth supplement (crude extract from bovine brain), penicillin (50 U/ml), streptomycin (50 U/ml), 2 mmol/l glutamine, and 0.1 mg/ml sodium heparin. Aliquots of cells were preserved frozen between passages 1 and 3. For all experiments, HUVECs were used at passages 4 or below and collected from a confluent dish. Cells were treated with 10 Units of rHEPO (a gift from Amgen) and cells were collected at 2 and 5 h after stimulation.
Epo transgenic mice
The full-length human Epo cDNA (HindIII-ApaI) was cloned into the HpaI site of the plasmid bMHC, which contains the beta myosin heavy chain promoter and 5V untranslated sequence of the hEpo start and termination codons, as well as a human growth hormone 3VUT and poly A sequence (Rindt et al., 1993) . Transgenic mice were made by pronuclear injection and founder mice were identified by PCR analysis using primers of 5V-ACTCCTGAGTGCT-GAGCA-3Vand 5V-CCTAGTCAAACAAAATGATGCA-3V, which amplifies a fragment of 800 bp. Five founders survived to adulthood but three died 4-7 weeks after birth due to, at least in part, spleenomegaly and extremely high hematocrit (97%). Two surviving lines, with hematocrit ranging 60-75%, were used for further studies.
FITC-lectin injection
Half milliliter of FITC-Lectin (Vector Laboratories, 40 Ag/ml in PBS) was injected into each mouse via tail vein under anesthesia (40 Al/mouse of ketamine 100 mg/ml and xylazine 20 mg/ml mixed 4:1 solution). One minute later, the mice were perfused with 1% paraformaldehyde (in PBS) for 2 min and then perfused with PBS for 2 min by cardiac perfusion. Then, the peritoneal membranes were dissected out, mounted on slide, and observed under fluorescent microscope.
Real-time quantitative PCR
Assays were performed using an Applied Biosystems 7700 sequence detector. Briefly, 1 Ag of total RNA was reverse transcribed with random hexamers using the Taqman reverse transcription reagent kit (Applied Biosystems) according to the manufacturer's protocol. Each Taqman reaction (50 Al) contained 50 ng of cDNA, 900 nM forward primer, 900 nM reverse primer, 100 nM duallabeled fluorogenic probe (IDT), and 25 Al of Universal PCR Master mix (Qiagen). PCR thermocycling parameters were 958C for 10 min, 40 cycles of 958C for 15 s, and 608C for 1 min. All samples were analyzed for 36B4 expression in parallel. The quantitative expression values were extrapolated from standard curves for VEGF or 36B4. Each sample was run in duplicate and was normalized to 36B4. The replicates were then averaged and fold induction was determined. Statistical analysis of mRNA expression data was performed by using the twotailed, homoscedastic t test. Probe and primer sequences are available upon request.
Results
Differential expression of Epo and EpoR during early vasculogenesis
The vascular system develops earlier during embryogenesis, both extraembryonically and intraembryonically, to satisfy the metabolic requirements for gastrulation and organogenesis. To study the possible roles of EPO and EPOR in early vasculogenesis, we performed detailed in situ hybridization analysis on E6.5-E9.0 embryos to investigate the timing and location of Epo and EpoR expression.
Whole-mount in situ hybridization analysis revealed that EpoR expression starts as early as E7.5 in the extraembryonic coelemic cavity and mesoderm derived allantois (all, arrows) (Figs. 1a, d) . This expression pattern continues until late neural fold stage, at which time EpoR expression is clearly evident in the yolk sac blood islands (bi) ( Fig. 1b ). During early embryogenesis, vasculogenesis in the yolk sac blood islands is closely associated with primitive hematopoiesis. Blood islands are formed by aggregation of mesoderm cells: Cells at the periphery of these aggregates differentiate into endothelial precursors, while cells inside become primitive blood cells (Risau, 1991) . Fusion of these blood islands eventually results in the formation of a continuous vascular channel system throughout the yolk sac. EpoR expression can be detected in both endothelial cells (green arrow) and primitive blood cells (red arrow, Fig.  1e ). At E9.0, EpoR expression is strong in the extraembryonic vessel networks (yolk sac vasculature, ysv; Fig. 1c ) as well as vitelline vessels (Fig. 1f ), which develop embryonically and are responsible for connecting the embryonic vasculature with the yolk sac vasculature (Rugh and Somogyi, 1968) .
In contrast to high levels of EpoR expression in extraembryonic tissues, Epo, which encodes the only known ligand for the EPOR, is undetectable, either extra-or intraembryonically during these stages of embryonic development (Figs. 1g-i). Thus, similar to initiation of primitive erythrocytes in the yolk sac (Lee et al., 2001; Lin et al., 1996; Wu et al., 1995) , the initiation and formation of the extraembryonic vasculature is probably EPO-independent (see below). 
Overlapping expressions of Epo and EpoR during midgestation
Around E8.5-9.0, the embryonic vessels connect with the extra-embryonic vasculature through umbilical and vitelline vessels and fetal circulation begins. The yolk-sacderived primitive nucleated red blood cells fill the embryonic vasculature. One day later, the liver rudiment is formed and soon receives hematopoietic stem cells and progenitors generated from the yolk sac or/and from the aorta-genital ridge-mesonephros (AGM) region. Figs. 2a and b show the overlapping expression of Epo and EpoR at E10.0 in the vasculature, which leads to the hepatic primordium (hpv). At E10.5, both Epo and EpoR are expressed in the dorsal aorta (da, Figs. 2c,d ), a site enriched in definitive hematopoietic stem cells (Dieterlen-Lievre and Martin, 1981; Medvinsky and Dzierzak, 1996) , suggesting that EPO may play an autocrine role in the expansion of the erythroid/megakaryocyte co-progenitors or erythroid pro-genitor cells in these regions. The overlapping expression of Epo and EpoR during this stage of embryonic development fits precisely the roles of EPO and EPOR in definitive erythropoiesis since targeted disruption of EpoR or Epo leads to a complete block in fetal liver erythropoiesis and causes embryonic lethality (Lin et al., 1996; Wu et al., 1995) . Whole-mount in situ hybridization analysis also indicated that both EpoR ( Fig. 2e) and Epo (Fig. 2f ) are expressed in the intersomitic vessels, with EpoR expression extending more rostral and at higher levels as compared to Epo expression. The fact that Epo expression is mainly restricted to the caudal intersomitic vessels, which are less mature than the rostral ones, suggest the possible involvement of EPO signaling in initiation of angiogenesis.
Normal vasculogenesis in Epo À/À and EpoR À/À embryos Functional significance of Epo and EpoR expression in the vessels outside of the heart was ascertained by further examination of Epo À/À and EpoR À/À embryos. Blood vessel development consists of two distinct phases, vasculogenesis and angiogenesis. Vasculogenesis is a process in which individual endothelial progenitors assemble vessels de novo. This contrasts with angiogenic assembly, in which new vessels arise from existing vessels through endothelial branching, sprouting, migration, proliferation, and anastomic interconnection with endothelial cells residing in existing vessels (Daniel and Abrahamson, 2000) . Studies performed in quail-chick chimeras suggest that vasculogenesis mainly accounts for the formation of the heart, dorsal aorta, cardinal and vitelline vessels, as well as the extraembryonic vessels of the yolk sac Poole, 1988, 1991; Pardanaud et al., 1989) . Angiogenesis is thought to be responsible for the formation of vessels such as the intersomitic arteries and the vessels in individual organs (Coffin and Poole, 1988) . As shown in Fig. 3 , no significant differences in vascular patterning were detected in the null embryos, E9.5 or younger, as compared to the WT or heterozygous littermates. Both intra-(lower panels, arrows point to dorsal aorta) and extra-embryonic vasculatures (upper panels) are well developed in the mutant embryos (Fig. 3A) . PECAM-1 staining, a specific marker for vascular endothelial cells, on the mutant yolk sac whole mounts and embryonic sections further revealed that the extraembyonic vessel network and the diameter of the mutant dorsal aorta and the intensities of PECAM-1 staining are comparable to that of the WT littermates (Fig. 3B) . Because earlier endothelial cell differentiation and formation of blood islands, dorsal aorta, heart, and primordial vasculature are normal in Epo À/À and EpoR À/À embryos and yolk sacs, our results suggest that earlier vasculogenesis is EPO and EPOR independent, which is consistent with our expression studies ( Figs. 1 and 2) .
Angiogenesis defects in Epo À/À and EpoR À/À embryos Starting from E10.5, 1.5 days after the commencement of blood circulation, which connects the extra-embryonic compartment with the embryo proper, both Epo À/À and EpoR À/À embryos appeared pale due to the absence of definitive erythropoiesis (Lee et al., 2001; Wu et al., 1995) . Interestingly, both mutant embryos also showed defects in the second wave of blood vessel formation, especially in the head region where active angiogenesis takes place. To confirm that this observation is not simply due to the lack of red blood cells in the vessels, we performed whole-mount PECAM-1 staining. The WT head contains well-branched blood vessel networks, whereas the complexity of cranial vasculatures in Epo À/À and EpoR À/À embryos was decreased: with narrower vessel diameter and fewer branches (Fig. 4, upper panels) . PECAM-1 staining is also weaker in both mutant intersomitic vessels ( Fig. 4 , middle panels), where high levels of Epo and EpoR expression are detected in the WT embryos by in situ hybridization analysis ( Figs. 2e,f) . This angiogenesis defect happens 2 days before the onset of observable cardiac defects (Wu et al., 1999) and is therefore likely to be a primary defect in angiogenesis.
At E12.5, angiogenesis defects became even more severe. We performed PECAM-1 staining on embryonic sections across the neural tube areas since (1) angiogenesis is very active during this stage of embryogenesis; and (2) high levels of both Epo and EpoR expressions can be detected in the neural tube region (Yu et al., 2002 and our unpublished observation). Lower panels in Fig. 4 clearly demonstrated angiogenesis defects in the neural tube regions: capillary sprouting is severely diminished in both mutants, as compared to the WT control where angiogenic sprouting is numerous in the neural tube and surrounding mesenchyme tissues. Taken together, these results suggest that EPO and EPOR are vital factors for angiogenesis but dispensable for vasculogenesis. Overexpression of Epo leads to increased vascularization and partial rescue of the angiogenic defects in Epo À/À embryos If the above defects were a direct result of lacking EPO or EPOR signaling, we would expect to rescue the vascular defects of Epo À/À embryos with an Epo transgene. For this, we generated transgenic lines carrying human Epo cDNA (see Materials and methods), using bMHC promoter (Rindt et al., 1993) . Because EPO is a secreted hormone, its effects will be seen systemically. Five founders survived to adulthood but three died 4-7 weeks after birth due to, at least in part, spleenomegaly and extremely high hematocrit (data not shown). Two surviving lines, with hematocrit ranging 60-75%, were used for further studies.
Based on RT-PCR analysis, hEpo transgene expression can be detected as early as E11 (Tran and Sucov, unpublished observation). As a result of overexpression of hEpo, a significant increase in the number of vessels, as visualized by FITC-labeled lectin (Fig. 5A, upper right), was observed in adult mice of two independent transgenic lines. We also detected significant morphological changes in the vessel structures. Instead of straight small vessels branching out from the large vessels, the transgenic mice contained abundant tortuous vessels (Fig.  5A, lower right) . When crossed to EPO-deficient mice, we found that the vascular defects in the null embryos were partially rescued by the hEpo transgene expression (Fig. 5B) .
EPO and the expression of angiogenic factors
Vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) are two important factors involved in the vascular formation during embryogenesis. VEGF is crucial for de novo vasculogenesis, the first wave of vasculogenesis, as well as for angiogenesis. Ang-1, on the other hand, has less effect on vasculogenesis but is indispensable for angiogenesis. To investigate the possible mechanism involved in EPO-controlled angiogenesis, we first compared the expression levels of Vegf and Ang-1 in E12.5 EpoR +/+ and EpoR À/À embryonic head region by Northern blot analysis. Interestingly, the expression of Vegf is up-regulated by at least 4-fold in the receptor null embryos (Fig. 6A, left  panel) , which is most likely due to the hypoxic condition caused by erythropoietic defects (Wu et al., 1995) , since Vegf expression levels are comparable in the placenta tissue of WT and mutant embryos (Fig. 6A, right panel) , a tissue that is not hypoxic due to maternal blood circulation. However, the expression of Ang-1 is reduced by 2-fold, as compared with WT controls (Fig. 6A, left panel) , suggesting that the EPO/EPOR signaling pathway may somehow modulate Ang-1 expression.
To prove that the decrease in Ang-1 levels is a direct result of the lack of EPO signaling, we employed HUVEC cells as well as primary murine aortic-derived endothelial cells (data not shown), which express the endogenous EpoR and can respond to EPO stimulation (Anagnostou et al., 1990 (Anagnostou et al., , 1994 Carlini et al., 1995) . Consistent with our in vivo studies, EPO stimulation under normoxic conditions resulted in a 2-to 4-fold increase in Ang-1 expression in HUVEC cells by Northern blot analysis (Fig. 6B, left) , or 2.5-fold based on Q-PCR (Fig. 6B, right) . Interestingly, under the normoxic condition, Vegf levels are also induced upon EPO stimulation (Fig. 6B) . This provides the first evidence that EPO/EPOR signaling pathway controls the expressions of Ang-1 and Vegf, two crucial angiogenic factors, and suggests that decreased Ang-1 expression may directly or indirectly contribute to the angiogenesis defects seen in the mutant embryos.
Discussion
In this study, we addressed the potential roles of EPO and EPOR in angiogenesis. Our in situ hybridization analysis Fig. 4 . Analysis of angiogenesis defects in the mutant embryos. Upper and middle panels, embryonic stage 10.5. Notice clear defects of vascular network in the head region (upper panels) or intersomitic region (middle panels) of both mutant embryos based on whole mounts for PECAM staining. Lower panels, embryonic stage 12.5. PECAM-stained sections show lack of extensive vascular network in neural tube regions in both types of mutant animals. Capillary sprouting is severely diminished in the neural tube in the mutant embryos, as compared to the WT control where angiogenic sprouting is numerous (arrowheads). clearly demonstrated that Epo and EpoR are expressed in situ in the vasculature. By analyzing Epo À/À and EpoR À/À mice as well as mice overexpressing Epo, we also provided the first genetic evidence for the roles of EPO and EPOR in angiogenesis.
EPO and EPOR are crucial for angiogenesis
The formation of new blood vessels (angiogenesis) is essential for embryonic development and contributes to the pathogenesis of numerous disorders. In contrast, insufficient angiogenesis may lead to tissue ischemia and failure. The effect of EPO on in vivo vasculogenesis has not been previously elucidated. However, the potential roles of EPO and EPOR in vascular function have been indicated in both in vitro and semi-in vivo studies: rEPO has been shown to increase microvascular branch formation from rat aortic rings in a standard angiogenic assay. In addition, rEPO has been shown to up-regulate expression of several genes involved in vascular function, signal transduction, and energy transfer, in cultured endothelial cells (Banerjee et al., 2000; Carlini et al., 1995; Fodinger et al., 2000; Heidenreich et al., 1991; Wang and Vaziri, 1999) . Recent studies also link EPO with malignant tumor growth (Yasuda et al., 2003) , at least in part, due to its angiogenic effects (Ribatti et al., 2003) . Our study demonstrates that EPO and EPOR regulate angiogenesis in vivo, a process involving the formation of new vessels on existing vessels, but not de novo vasculogenesis. Interestingly, vasculatures in both Epo À/À and EpoR À/À embryos are equally affected, suggesting EPOR is the signaling receptor for EPO in regulating angiogenesis.
The defects seen in the mutant vasculatures fit precisely with the patterns of Epo and EpoR expressions: EpoR is expressed in the yolk sac blood islands and vascular structures. However, Epo is absent during this early stage of embryogenesis, the period that vasculogenesis takes place. Thus, similar to initiation of primitive erythropoiesis in the yolk sac blood islands (Lee et al., 2001; Wu et al., 1995) , the initiation of vascular structures is also EPOindependent. It is only by E9.0-E10.5 when EPO starts to be produced intraembryonically that angiogenesis defects become apparent.
Recently, Suzuki et al. (2002) showed rescue of lethality of EpoR null mutant mice upon expression of EpoR under an erythroid specific promoter GATA-1 and concluded that nonhematopoietic expression of EpoR is dispensable to normal mouse development. This discrepancy could be due to the (1) different EpoR-deficient animals were used. The EpoR knockout mice Suzuki et al. used carries an exon-3specific deletion (Kieran et al., 1996) that leads to erythroid defects less severe than our mutant line in which the promoter and exons 1-6 are completely deleted (Wu et al., 1995) . Importantly, the erythroid colony formation defects of our EpoR À/À progenitors cannot be rescued by TPO (Wu, unpublished observation) , different from what was reported (Kieran et al., 1996) . (2) The angiogenesis defects seen in Epo-and EpoR-deficient embryos may happen transiently during a specific stage of embryonic development, similar to the erythroid defects seen in RXRa À/À embryos at E10. 25-11.25 (Makita et al., 2001) or Stat5a À/À 5b À/À mice during fetal stage (Socolovsky et al., 1999) . (3) Because GATA-1 is expressed in the Flk1+ extra-embryonic mesoderm, as well as the hematopoietic cells (Fujimoto et al., 2001) , the EpoR transgene, under the control of the GATA-1 promoter, may be expressed at low levels in the hemangioblasts or vessel endothelium, and although difficult to be detected, sufficient to rescue the vessel defects. Further investigation will help in distinguishing these possibilities.
Angiogenic defects and hypoxia
The lack of EPO or EPOR is clearly accompanied by alterations in the relative oxygen tensions in the mutant animals. However, the angiogenesis defects described in this study are unlikely due to general hypoxia. Hypoxia will induce the expression and activation of transcription factor HIF-1a, which in turn activates gene expression, such as Vegf and promotes vessel formation. Therefore, hypoxia conditions usually cause increased angiogenesis, rather than decreased angiogenesis, as we observed in this study. Furthermore, the onset and location of angiogenesis defects correlate well with endogenous Epo expression and EPO production, suggesting that EPO/EPOR plays an active role in promoting new vessel formation.
During vertebrate embryogenesis, blood cell formation and vasculogenesis are intertwined temporally and spatially to satisfy the metabolic requirements of the developing embryo. It is interesting that EpoR is expressed early in the murine yolk sac where the blood cell and vessel formation takes place, and EPO and EPOR are required for the second, definitive waves of erythropoiesis (Lee et al., 2001) as well as the second wave of vasculogenesis, as indicated in this study. Whether the low shear stress, i.e., decreased hematocrit due to anemia, in the vasculature of the mutant embryo could contribute to the angiogenesis defects observed in this study needs to be further investigated. However, studies on zebrafish mutants affecting either the 2) and WT embryo (lane 1) heads (left) and placenta (right). Vegf expression is significantly increased by 4-fold in the mutant embryos as compared to the WT (upper panel). The same blot was reprobed with Ang-1 probe (middle). Ang-1 expression is significantly lower (about 2 fold) in the null embryo compared to the WT. Vegf expression, on the other hand, is not changed in the placental tissues: 15 and 25 Ag of total RNA were loaded, respectively. Actin is used as loading control. (B) The levels of Ang-1 and Vegf were determined by Northern blot analysis (left) or real-time quantitative PCR (right). EPO (10 U) stimulation leads to increased Vegf and Ang-1 expression at 2 and 5 h. cardiovascular system or hematopoiesis (Paw and Zon, 2000; Weinstein et al., 1996) seem to suggest that the formation of the zebrafish circulation system are not severely influenced by the low shear stress caused by hematopoietic defects.
EPO and Vegf/Ang-1 expressions
Although the precise mechanism by which EPO regulates angiogenesis remains to be studied, it is most likely initiated by binding of EPO to EPOR on endothelial cells and activation of the downstream signaling cascades, since both Epo-and EpoR-deficient mice demonstrated identical phenotypes throughout our studies.
We have shown decreased Ang-1 expression in the mutant embryos. Conversely, EPO stimulation leads to increased Ang-1 levels, indicating that EPO may regulate angiogenesis through, at least in part, by modulating Ang-1 expression. The mechanism whereby EPO affects Ang-1 expression remains to be further elucidated. Recent studies have demonstrated that Ang-1 induces endothelial cell sprouting, endothelial cell migration, and tubule-like structure formation in vitro (Fujikawa et al., 1999; Hayes et al., 1999; Koblizek et al., 1998 ). In addition, increased branching and vessel density is observed in vivo upon overexpression of Ang-1, providing strong evidence of an active role for Ang-1 in both embryonic and adult angiogenesis (Suri et al., 1998) . Interestingly, increased vessel density is also evident in hEpo transgenic animals.
Ang-1 regulates endothelial cells by binding to its cognate receptor, Tie2 (Yancopoulos et al., 2000) . Recent studies suggest that EPO and Ang-1 may employ similar signaling pathways for their biological functions; for example, STAT3 and STAT5 were found to be potential targets of Tie2 activation. As STAT3 and/or STAT5 have been implicated in the regulation of EPO-mediated biological effects (for a review, see (Akira, 1999) , some of the Tie2 functions in endothelial cells may be regulated by the cross-talk from the EPOR signaling pathway. Both Epo and Vegf are under the control of HIF-1a, a transcription factor whose activity is up-regulated under hypoxic conditions. It is interesting to observe upregulation of Vegf expression upon EPO stimulation under normoxic conditions. The precise mechanism and biological significance of such regulation needs further investigation.
Multifunction of EPO and EPOR: a mode of action
Generation of animals lacking either Epo or EpoR genes established genetic systems to address the function of this ligand/receptor pair in erythropoiesis (Wu et al., 1995) , in cardiac morphogenesis (Wu et al., 1999) , in neurogenesis (Yu et al., 2002) , and in angiogenesis (this study). The mutant phenotypes observed in the mutant mice fit precisely the temporal and spatial expression patterns of Epo and EpoR genes. First, EpoR is always expressed before that of Epo during embryonic development to bprimeQ or prepare cells to respond to EPO stimulation. Secondly, Epo and EpoR expression are spatially separated in the yolk sac: EpoR is expressed in the yolk sac blood island and vasculatures, but Epo expression is absent in the yolk sac. This spatially uncoupled expression pattern provides a cellular mechanism as to why the initiation of primitive erythropoiesis and primitive vasculogenesis in the yolk sac are independent of EPO and EPOR even though the cells are fully competent to respond to EPO stimulation. Only until later when both Epo and EpoR are co-expressed intraembryonically can defects in definitive erythropoiesis in the fetal liver, hypoplasia in the myocardium, and defects in angiogenesis be observed.
